



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Mundy *et al.* Art Unit : 1644
Serial No. : 09/805,840 Examiner : Maher M. Haddad
Filed : March 13, 2001 Conf. No. : 4957
Title : METHODS OF TREATING MULTIPLE MYELOMA AND MYELOMA-
INDUCED BONE RESORPTION USING INTEGRIN ANTAGONISTS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REPLY TO ACTION OF MAY 19, 2006

Claims 1, 2, 4, 5, 9, 31, 32, 40, and 42-48 are pending in the application. In reply to the Office Action dated May 19, 2006, Applicants submit the following remarks.

35 U.S.C. § 103(a)

The Examiner rejected claims 1, 2, 4, 5, 9, 31, 32, 40 and 42-48 under 35 U.S.C. § 103(a) as being unpatentable over U.S. Patent No. 6,692,742 (hereafter "Nakamura"; IDS Ref. No. AD) in view of Masellis-Smith *et al.* (IDS Ref. No. AJ) or Lokhorst *et al.* (Blood 84:2269-2277, 1994, of record). The rejection is respectfully traversed.

The position of the Office appears to rely on the following. Nakamura describes a combination of melphalan and an anti-IL-6 receptor antibody to treat multiple myeloma (MM). Masellis-Smith *et al.* teaches that anti-VLA4 antibodies that bind $\alpha_4\beta_7$ inhibited MM blood B cell interactions with bone marrow fibroblasts *in vitro*. Lokhorst *et al.* teaches that anti-VLA-4 antibodies inhibited binding of purified myeloma cells to long term bone marrow cultures (LTBMC) from patients with multiple myeloma. Lokhorst *et al.* also teaches that inhibition of

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date of Deposit

10/19/06

Signature

Typed or Printed Name of Person Signing Certificate